Edition:
United States

Strongbridge Biopharma plc (SBBP.OQ)

SBBP.OQ on NASDAQ Stock Exchange Global Select Market

7.65USD
20 Apr 2018
Change (% chg)

$0.05 (+0.66%)
Prev Close
$7.60
Open
$7.55
Day's High
$7.75
Day's Low
$7.45
Volume
24,738
Avg. Vol
73,006
52-wk High
$9.25
52-wk Low
$4.00

Select another date:

Wed, Feb 28 2018

BRIEF-Strongbridge To Host Conference Call On March 12 To Announce Fourth Quarter And Year-End 2017 Results

* STRONGBRIDGE BIOPHARMA PLC TO HOST CONFERENCE CALL ON MARCH 12, 2018 TO ANNOUNCE FOURTH QUARTER AND YEAR-END 2017 FINANCIAL RESULTS AND PROVIDE CORPORATE UPDATE Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

BRIEF-Strongbridge Biopharma Announces Pricing Of Public Offering

* STRONGBRIDGE BIOPHARMA PLC ANNOUNCES PRICING OF PUBLIC OFFERING OF ORDINARY SHARES

BRIEF-Strongbridge Biopharma Announces Proposed Public Offering Of 5 Mln Ordinary Shares

* STRONGBRIDGE BIOPHARMA PLC ANNOUNCES PROPOSED PUBLIC OFFERING OF 5 MILLION ORDINARY SHARES Source text for Eikon: Further company coverage:

BRIEF-Strongbridge Biopharma Receives Notice Of Allowance From U.S. Patent And Trademark Office For New Patent Covering RECORLEV

* STRONGBRIDGE BIOPHARMA RECEIVES NOTICE OF ALLOWANCE FROM U.S. PATENT AND TRADEMARK OFFICE FOR NEW PATENT COVERING RECORLEV™ (LEVOKETOCONAZOLE) FOR THE TREATMENT OF CUSHING’S SYNDROME

BRIEF-Strongbridge Announces Acquisition Of U.S., Canadian Rights To Macrilen From Aeterna Zentaris

* STRONGBRIDGE BIOPHARMA PLC ANNOUNCES ACQUISITION OF THE U.S. AND CANADIAN RIGHTS TO MACRILEN™ (MACIMORELIN) FROM AETERNA ZENTARIS

BRIEF-Aeterna Zentaris Enters Licensing Agreement With Strongbridge For Macrilen In U.S., Canada

* AETERNA ZENTARIS ENTERS INTO LICENSING AND ASSIGNMENT AGREEMENT WITH STRONGBRIDGE FOR MACRILEN™ (MACIMORELIN) IN THE U.S. AND CANADA

BRIEF-Strongbridge Gets Letters From Offices Of U.S. Senators Requesting Information On Marketing & Sales Of Keveyis

* STRONGBRIDGE BIOPHARMA - ON DEC 19, RECEIVED LETTERS FROM OFFICES OF U.S. SENATORS THAT REQUEST INFORMATION RELATING TO MARKETING & SALES OF KEVEYIS

BRIEF-Strongbridge Biopharma Q3 loss per share $0.98

* Strongbridge Biopharma Plc provides corporate update and reports third quarter 2017 financial results

Select another date: